Literature DB >> 11380303

Reasoning about the optimal duration of prophylactic antipsychotic medication in schizophrenia: evidence and arguments.

L J Bosveld-van Haandel1, C J Slooff, R J van den Bosch.   

Abstract

OBJECTIVE: To review evidence-based literature regarding the necessary duration of antipsychotic relapse prevention in schizophrenia and related psychoses.
METHOD: A computerized search was performed on Medline, Embase Psychiatry and PsycLIT which covered the period 1974-99. We also used cross-references.
RESULTS: Although schizophrenia refers mainly to an intrinsic biological vulnerability, only maintenance studies with a follow-up of 2 years at most are available. Relapses appear unpredictable and occur even after long-term successful remission during antipsychotic treatment.
CONCLUSION: Since rehabilitation efforts have effects only after long-term endeavours, antipsychotic relapse prevention should be maintained for long periods. It is reasonable to treat patients suffering from schizophrenia and related psychoses for longer periods than indicated by the current guidelines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11380303     DOI: 10.1034/j.1600-0447.2001.00089.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  2 in total

1.  Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.

Authors:  Diana De Graeve; Ann Smet; Angelika Mehnert; Sue Caleo; Houda Miadi-Fargier; Guillermo Jasso Mosqueda; Damien Lecompte; Joseph Peuskens
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

2.  Detection of psychosis by mental health care services; a naturalistic cohort study.

Authors:  Nynke Boonstra; Lex Wunderink; Sjoerd Sytema; Durk Wiersma
Journal:  Clin Pract Epidemiol Ment Health       Date:  2008-12-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.